UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
Photronics shows strong execution, buybacks, and solid demand drivers from AI, EUV, and OLED technologies supporting growth. See why PLAB stock is a buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback